Kuros Biosciences AG reports a 155% increase in MagnetOs sales and FDA clearance, with a positive EBITDA of CHF 3.9M in Q1 2024.
Kuros Biosciences AG reports Q1 2024 highlights, including 155% increase in direct MagnetOs sales to CHF 13.9M from CHF 5.4M in Q1 2023. Total Kuros Medical Devices segment sales accelerated to CHF 13.9M, with a positive EBITDA of CHF 3.9M. Cash and cash equivalents amounted to CHF 13.7M, funds available totaled CHF 23.5M. MagnetOs Putty received FDA 510(k) clearance and showed an 86% fusion rate in a recent clinical study.
April 24, 2024
3 Articles